JP2023503644A5 - - Google Patents

Info

Publication number
JP2023503644A5
JP2023503644A5 JP2022531426A JP2022531426A JP2023503644A5 JP 2023503644 A5 JP2023503644 A5 JP 2023503644A5 JP 2022531426 A JP2022531426 A JP 2022531426A JP 2022531426 A JP2022531426 A JP 2022531426A JP 2023503644 A5 JP2023503644 A5 JP 2023503644A5
Authority
JP
Japan
Prior art keywords
unsubstituted
pharmaceutically acceptable
acceptable salt
substituted
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022531426A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023503644A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/062333 external-priority patent/WO2021108640A1/en
Publication of JP2023503644A publication Critical patent/JP2023503644A/ja
Publication of JP2023503644A5 publication Critical patent/JP2023503644A5/ja
Pending legal-status Critical Current

Links

JP2022531426A 2019-11-27 2020-11-25 デュシェンヌ型筋ジストロフィーの治療のための化合物および方法 Pending JP2023503644A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962941549P 2019-11-27 2019-11-27
US62/941,549 2019-11-27
PCT/US2020/062333 WO2021108640A1 (en) 2019-11-27 2020-11-25 Compounds and methods for the treatment of duchenne muscular dystrophy

Publications (2)

Publication Number Publication Date
JP2023503644A JP2023503644A (ja) 2023-01-31
JP2023503644A5 true JP2023503644A5 (cg-RX-API-DMAC10.html) 2023-12-04

Family

ID=74046138

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022531426A Pending JP2023503644A (ja) 2019-11-27 2020-11-25 デュシェンヌ型筋ジストロフィーの治療のための化合物および方法

Country Status (8)

Country Link
US (1) US20230108783A1 (cg-RX-API-DMAC10.html)
EP (1) EP4065225A1 (cg-RX-API-DMAC10.html)
JP (1) JP2023503644A (cg-RX-API-DMAC10.html)
KR (1) KR20220147575A (cg-RX-API-DMAC10.html)
CN (1) CN115348883B (cg-RX-API-DMAC10.html)
AU (1) AU2020392220A1 (cg-RX-API-DMAC10.html)
CA (1) CA3166370A1 (cg-RX-API-DMAC10.html)
WO (1) WO2021108640A1 (cg-RX-API-DMAC10.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12018087B2 (en) 2018-08-02 2024-06-25 Dyne Therapeutics, Inc. Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject
US11168141B2 (en) 2018-08-02 2021-11-09 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
US12097263B2 (en) 2018-08-02 2024-09-24 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
US12370264B1 (en) 2018-08-02 2025-07-29 Dyne Therapeutics, Inc. Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject
WO2020028832A1 (en) 2018-08-02 2020-02-06 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
EP3830259A4 (en) 2018-08-02 2022-05-04 Dyne Therapeutics, Inc. MUSCLE TARGETED COMPLEXES AND THEIR USES IN THE TREATMENT OF FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY
WO2020219820A1 (en) 2019-04-25 2020-10-29 Avidity Biosciences, Inc. Nucleic acid compositions and methods of multi-exon skipping
WO2021154477A1 (en) 2020-01-31 2021-08-05 Dyne Therapeutics, Inc. Anti-transferrin receptor (tfr) antibody and uses thereof
US11969475B2 (en) 2021-07-09 2024-04-30 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
US11771776B2 (en) 2021-07-09 2023-10-03 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
US20250027082A1 (en) * 2021-11-15 2025-01-23 Novartis Ag Staggered triple lipid-modified nucleic acid compounds
CA3235963A1 (en) * 2021-11-15 2023-05-19 Novartis Ag Branched triple lipid-modified nucleic acid compounds
US12071621B2 (en) 2022-04-05 2024-08-27 Avidity Biosciences, Inc. Anti-transferrin receptor antibody-PMO conjugates for inducing DMD exon 44 skipping
IL316143A (en) 2022-04-15 2024-12-01 Dyne Therapeutics Inc Muscle targeting complexes and formulations for the treatment of myotonic dystrophy
EP4590311A2 (en) * 2022-09-21 2025-07-30 Sarepta Therapeutics, Inc. Dmd antisense oligonucleotide-mediated exon skipping efficiency

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4783443A (en) 1986-03-03 1988-11-08 The University Of Chicago Amino acyl cephalosporin derivatives
KR101981705B1 (ko) * 2010-05-28 2019-05-24 사렙타 쎄러퓨틱스, 인코퍼레이티드 변형된 서브유니트간 결합 및/또는 말단 그룹을 갖는 올리고뉴클레오타이드 유사체
JP6928025B2 (ja) * 2012-01-27 2021-09-01 バイオマリン テクノロジーズ ベー.フェー. デュシェンヌ型及びベッカー型筋ジストロフィーの治療のための改善された特徴を有するrna調節オリゴヌクレオチド
TWI864340B (zh) * 2014-10-10 2024-12-01 美商艾爾妮蘭製藥公司 用於抑制hao1(羥酸氧化酶1(乙醇酸鹽氧化酶))基因表現的組合物及方法
JP2018530560A (ja) * 2015-10-09 2018-10-18 サレプタ セラピューティクス, インコーポレイテッド デュシェンヌ型筋ジストロフィーおよび関連障害の処置のための組成物および方法
JP2019516679A (ja) * 2016-05-04 2019-06-20 ウェイブ ライフ サイエンシズ リミテッドWave Life Sciences Ltd. 生物活性剤に関する方法および組成物
US20190330626A1 (en) * 2016-07-15 2019-10-31 Ionis Pharmaceuticals, Inc. Compounds and methods for use in dystrophin transcript
WO2018193428A1 (en) * 2017-04-20 2018-10-25 Synthena Ag Modified oligomeric compounds comprising tricyclo-dna nucleosides and uses thereof
EP3687519A1 (en) * 2017-09-28 2020-08-05 Sarepta Therapeutics, Inc. Combination therapies for treating muscular dystrophy

Similar Documents

Publication Publication Date Title
CN102643267B (zh) 4-氨基-2-(2,6-二氧哌啶-3-基)异吲哚啉-1,3-二酮化合物的制备方法
JP6853193B2 (ja) 核酸複合体
JP2023139036A5 (cg-RX-API-DMAC10.html)
KR20240123832A (ko) 지질 나노입자 제형에 사용하기 위한 지질
AU2016334232A1 (en) Oligonucleotide compositions and methods thereof
EP3341479B1 (en) Lna-g process
TW202220695A (zh) 寡核苷酸之全身遞送
AU2020201707B2 (en) Oligonucleotide compositions and methods of making the same
JP2023503722A5 (cg-RX-API-DMAC10.html)
JP7348064B2 (ja) 分子を経膜送達するための化合物及び方法
CN114716490B (zh) GalNAc簇亚磷酰胺和靶向治疗性核苷
WO2016060135A1 (ja) モルフォリノオリゴヌクレオチドの製造方法
US20220010348A1 (en) Method for producing oligonucleotide having phosphorothioated site
TW202613310A (zh) 含有三氮唑結構的GalNAc化合物及其寡核苷酸綴合物
BR112019014547A2 (pt) Oligonucleotídeo de fita simples
EP3601309A1 (en) Orthogonal protecting groups for the preparation of stereodefined phosphorothioate oligonucleotides
JP2025520520A (ja) PCSK9遺伝子活性を調節するsiRNA分子
US12264174B2 (en) Process for preparing imetelstat
CN121194983A (zh) 5'-膦酸酯修饰的核苷类似物及其制备的寡核苷酸
JP2016130232A (ja) オリゴヌクレオチド
TWI848981B (zh) 新穎亞磷醯胺、及髮夾型單股rna分子之製造方法
TW202440920A (zh) 雙環脫鹼基核酸類似物以及由它們製備的寡聚化合物
US20230242587A1 (en) Thyclotides
JP2016202097A (ja) 核酸固相合成用リンカー及び担体
JP7854977B2 (ja) 分子の膜貫通送達のための化合物および方法